Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
Eur Rev Med Pharmacol Sci
; 24(10): 5783-5787, 2020 May.
Article
in English
| MEDLINE | ID: covidwho-542679
ABSTRACT
In December 2019, Coronavirus disease 2019 (COVID-19) emerged in Wuhan and rapidly spread throughout China and the rest of the world. COVID-19 is currently a global pandemic. There are cytokine storms in severe COVID-19 patients. Interleukin-6 plays an important role in cytokine storm. Tocilizumab is a blocker of interleukin-6 receptor, which is likely to become an effective drug for patients with severe COVID-19. Here, we reported a case in which tocilizumab was effective for a critical COVID-19 patient.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Antibodies, Monoclonal, Humanized
Type of study:
Case report
Limits:
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Eur Rev Med Pharmacol Sci
Journal subject:
Pharmacology
/
Toxicology
Year:
2020
Document Type:
Article
Affiliation country:
Eurrev_202005_21372
Similar
MEDLINE
...
LILACS
LIS